A Randomized, Double-blind, Placebo-controlled, Phase I Study of the Safety of Multi-vessel Intra-coronary Delivery of Allogeneic Human Cardiosphere-Derived Stem Cells in Patients With Dilated Cardiomyopathy (DCM)

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase I Study of the Safety of Multi-vessel Intra-coronary Delivery of Allogeneic Human Cardiosphere-Derived Stem Cells in Patients With Dilated Cardiomyopathy (DCM)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs CAP-1002 (Primary)
  • Indications Dilated cardiomyopathy
  • Focus Adverse reactions
  • Acronyms DYNAMIC
  • Sponsors Capricor Therapeutics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 31 Oct 2016 Top-line 12-month data from this trial was announced in June 2016, according to a Capricor Therapeutics media release.
    • 31 Oct 2016 Results published in the Capricor Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top